Relationship between Effect of Induction Chemotherapy and Prognosis in AML Patients.
10.19746/j.cnki.issn.1009-2137.2021.05.008
- Author:
Bo-Ran WANG
1
;
Hai-Bo ZHANG
1
;
Qi-Ning YU
1
;
Ren-Na WU
2
Author Information
1. Department of Hematology, Affiliated Hospital of Chifeng University, Chifeng 024001, Inner Mongolia Autonomous Region, China.
2. Department of Hematology, Affiliated Hospital of Chifeng University, Chifeng 024001, Inner Mongolia Autonomous Region, China E-mail: 331591235@qq.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Child, Preschool;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Prognosis;
Recurrence;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(5):1417-1423
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the relationship between effect of induction chemotherapy and prognosis in acute myeloid leukemia (AML) patients.
METHODS:The clinical data of 146 adult AML patients treated in Affiliated Hospital of Chifeng University from March 2015 to March 2018 were enrolled and retrospectively analyzed. Day 14 bone marrow biopsy (D14BM) cellularity and blast proportion, daily peripheral blood blast (PBB) clearance rate, time to PBB clearance and etc. were primarily observed after induction chemotherapy. All the patients were divided into Non-relapse survival group, Relapse survival group, Non-relapse death group and Relapse death group according to survival and recurrence situation during 2-year follow-up. The survival of the patients was analyzed by Kaplan-Meier. Univariate analysis of prognostic factors were performed by ordinal Logistic regression, and ROC curve was used to assess the prediction efficiency of those factors for the 2-year overall survival (OS) and relapse of the patients.
RESULTS:A total of 138 patients were included since 8 cases failed to be assessed clinically. Their 2-year OS rate was 65.94%. Age of the patients in Non-relapse survival group was lower than that in Relapse death group. The D14BM cellularities in Non-relapse survival group and Relapse survival group were lower than those in Relapse death group (P<0.05). Daily PBB clearance rates in Non-relapse survival group and Relapse survival group were higher than those in Non-relapse death group and Relapse death group (P<0.05). There was a statistical difference among the four groups in the number of cycles of induction chemotherapy (P<0.05). The survival rate within 2 years in the patients with D14BM cellularity≤10% was higher than that in patients with cellularity >10%, while it was higher in patients with daily PBB clearance rate >20% than those with clearance rate≤20% (P<0.05). Age (HR=1.102, P=0.000), D14BM cellularity (HR=1.252, P=0.000) and the cycles of induction chemotherapy≥3 (HR=1.703, P=0.000) were the risk factors affecting the prognosis of AML patients, while daily PBB clearance rate was a protective factor (HR=0.799, P=0.000). The AUC of age, daily PBB clearance rate and D14BM cellularity in predicting 2-year OS of AML patients was 0.738, 0.817 and 0.807, respectively, whereas in predicting relapse within 2 years it was 0.691, 0.647 and 0.711, respectively. There was no statistical difference among the three factors in the sensitivity of 2-year OS (68.11%, 85.12%, 74.49%) and 2-year relapse (50.00%, 64.13%, 61.60%) (P>0.05).
CONCLUSION:Bone marrow biopsy results and PBB clearance rate are related to prognosis in AML patients, which can offer certain predictive value in assessing 2-year OS of patients.
